Lymphoma treatment showdown: which drug combo wins?
NCT ID NCT07492407
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at three different drug combinations for people newly diagnosed with a slow-growing blood cancer called marginal zone lymphoma. The goal is to see which combination works best to shrink tumors and keep the cancer from coming back, while also checking for side effects. About 131 patients will take part across multiple hospitals in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rituximab combined with lenalidomide, bendamustine, or lenalidomide plus other drugs
- What this could lead to
- If successful, this study could identify the most effective and safest first-line treatment for marginal zone lymphoma, improving outcomes for patients.
- What could go wrong
- This is a real-world observational study, not a controlled trial, so results may be less reliable. The study hasn't started yet, and it's relatively small (131 people).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MZL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.